Harbour Biomed Pharmaceuticals Signs Exclusive Licensing Agreement
January 15, 2025
Source: drugdu
32
On January 12, Harbour Biomed Pharmaceuticals (02142) announced that it has signed an exclusive licensing agreement with Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. and Windward Bio AG for HBM9378/SKB378. According to the agreement, the licensor will grant Windward Bio a global exclusive license to manufacture, develop, use, promote, sell, promise to sell, import, and otherwise commercialize HBM9378/SKB378 outside of Greater China and several Southeast Asian and Middle Eastern countries.
Under the agreement, the licensor has the right to receive up to a total of $970 million in upfront and milestone payments, as well as tiered royalties ranging from single-digit to double-digit percentages of net sales. The signing of this agreement is expected to help integrate the R&D, production, and commercialization capabilities of the licensor and Windward Bio, bringing HBM9378/SKB378 to the global market.
https://finance.eastmoney.com/a/202501123294354429.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- 2025 medical device global exhibition summary January 15, 2025
- 2025 Biopharmaceutical global exhibition summary January 15, 2025
- IPO Radar | Losing 1 billion yuan in one year, Maiwei Biotechnology seeks A+H listing, how long can it survive relying on external “blood transfusion”? January 15, 2025
- Johnson&Johnson’s new drug, Edatinib, has been approved for market in China | Medical Early Reference January 15, 2025
- United Imaging Medical, there are big moves in North America January 15, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
